1
|
Clark AL, Bruce Wirta S, Zhou M, Kazmi S, Goode KM, Pellicori P, Corda S, Balas B, Calado F, Cleland JGF. P6530What proportion of patients with heart failure are candidates for sacubitril/valsartan? Differences between guideline recommendations and regulatory labels. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- A L Clark
- Hull York Medical School (at University of Hull), Castle Hill Hospital, Department of Cardiology, Kingston upon Hull, United Kingdom
| | - S Bruce Wirta
- Novartis Sweden AB, Real World Evidence Center of Excellence, Stockholm, Sweden
| | - M Zhou
- IQVIA, Real-World Insights, Basel, Switzerland
| | - S Kazmi
- Hull York Medical School (at University of Hull), Castle Hill Hospital, Department of Cardiology, Kingston upon Hull, United Kingdom
| | - K M Goode
- Hull York Medical School (at University of Hull), Castle Hill Hospital, Department of Cardiology, Kingston upon Hull, United Kingdom
| | - P Pellicori
- Hull York Medical School (at University of Hull), Castle Hill Hospital, Department of Cardiology, Kingston upon Hull, United Kingdom
| | - S Corda
- Novartis, Basel, Switzerland
| | - B Balas
- Novartis, Basel, Switzerland
| | | | - J G F Cleland
- University of Hull, Kingston upon Hull, United Kingdom
| |
Collapse
|
2
|
Goode KM, Petrov DP, Vickman RE, Crist SA, Pascuzzi PE, Ratliff TL, Davisson VJ, Hazbun TR. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation. Biochim Biophys Acta Gen Subj 2017; 1861:1992-2006. [PMID: 28495207 DOI: 10.1016/j.bbagen.2017.05.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Revised: 04/20/2017] [Accepted: 05/05/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND Inhibition of Hsp90 is desirable due to potential downregulation of oncogenic clients. Early generation inhibitors bind to the N-terminal domain (NTD) but C-terminal domain (CTD) inhibitors are a promising class because they do not induce a heat shock response. Here we present a new structural class of CTD binding molecules with a unique allosteric inhibition mechanism. METHODS A hit molecule, NSC145366, and structurally similar probes were assessed for inhibition of Hsp90 activities. A ligand-binding model was proposed indicating a novel Hsp90 CTD binding site. Client protein downregulation was also determined. RESULTS NSC145366 interacts with the Hsp90 CTD and has anti-proliferative activity in tumor cell lines (GI50=0.2-1.9μM). NSC145366 increases Hsp90 oligomerization resulting in allosteric inhibition of NTD ATPase activity (IC50=119μM) but does not compete with NTD or CTD-ATP binding. Treatment of LNCaP prostate tumor cells resulted in selective client protein downregulation including AR and BRCA1 but without a heat shock response. Analogs had similar potencies in ATPase and chaperone activity assays and variable effects on oligomerization. In silico modeling predicted a binding site at the CTD dimer interface distinct from the nucleotide-binding site. CONCLUSIONS A set of symmetrical scaffold molecules with bisphenol A cores induced allosteric inhibition of Hsp90. Experimental evidence and molecular modeling suggest that the binding site is independent of the CTD-ATP site and consistent with unique induction of allosteric effects. GENERAL SIGNIFICANCE Allosteric inhibition of Hsp90 via a mechanism used by the NSC145366-based probes is a promising avenue for selective oncogenic client downregulation.
Collapse
Affiliation(s)
- Kourtney M Goode
- Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA
| | - Dino P Petrov
- Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA
| | - Renee E Vickman
- Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA
| | - Scott A Crist
- Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA
| | - Pete E Pascuzzi
- Purdue University Libraries Purdue University, West Lafayette, IN 47907, USA; Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA
| | - Tim L Ratliff
- Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA; Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA
| | - V Jo Davisson
- Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA; Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA
| | - Tony R Hazbun
- Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA; Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA.
| |
Collapse
|
3
|
Thomas FM, Goode KM, Rajwa B, Bieberich AA, Avramova LV, Hazbun TR, Davisson VJ. A Chemogenomic Screening Platform Used to Identify Chemotypes Perturbing HSP90 Pathways. SLAS Discov 2017; 22:706-719. [PMID: 28346089 DOI: 10.1177/2472555216687525] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Compounds that modulate the heat shock protein (HSP) network have potential in a broad range of research applications and diseases. A yeast-based liquid culture assay that measured time-dependent turbidity enabled the high-throughput screening of different Saccharomyces cerevisae strains to identify HSP modulators with unique molecular mechanisms. A focused set of four strains, with differing sensitivities to Hsp90 inhibitors, was used to screen a compound library of 3680 compounds. Computed turbidity curve functions were used to classify strain responses and sensitivity to chemical effects across the compound library. Filtering based on single-strain selectivity identified nine compounds as potential heat shock modulators, including the known Hsp90 inhibitor macbecin. Haploid yeast deletion strains (360), mined from previous Hsp90 inhibitor yeast screens and heat shock protein interaction data, were screened for differential sensitivities to known N-terminal ATP site-directed Hsp90 inhibitors to reveal functional distinctions. Strains demonstrating differential sensitivity (13) to Hsp90 inhibitors were used to prioritize primary screen hit compounds, with NSC145366 emerging as the lead hit. Our follow-up biochemical and functional studies show that NSC145366 directly interacts and inhibits the C-terminus of Hsp90, validating the platform as a powerful approach for early-stage identification of bioactive modulators of heat shock-dependent pathways.
Collapse
Affiliation(s)
- Fiona M Thomas
- 1 Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA
| | - Kourtney M Goode
- 1 Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA
| | - Bartek Rajwa
- 2 Bindley Bioscience Center, Purdue Discovery Park, Purdue University, West Lafayette, IN, USA
| | - Andrew A Bieberich
- 1 Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA
| | - Larisa V Avramova
- 2 Bindley Bioscience Center, Purdue Discovery Park, Purdue University, West Lafayette, IN, USA
| | - Tony R Hazbun
- 1 Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.,3 Purdue University Center for Cancer Research, West Lafayette, IN, USA
| | - V Jo Davisson
- 1 Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.,3 Purdue University Center for Cancer Research, West Lafayette, IN, USA
| |
Collapse
|
4
|
Goode KM, Thomas FM, Pascuzzi P, Davisson VJ, Hazbun TR. Abstract B89: Mechanistic assessment of heat shock network perturbation by novel chemotypes identified using chemogenomic screening. Mol Cancer Ther 2015. [DOI: 10.1158/1535-7163.targ-15-b89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The 90-kDa heat shock protein 90 (Hsp90) is a chaperone protein responsible for the folding and activation of numerous proteins disregulated in various cancers that drive oncogenesis. Consequently, inhibition of Hsp90 is thought to be an attractive anti-cancer therapeutic strategy, though to date, clinical success has been limited. Hsp90 inhibition leads to simultaneous degradation of multiple oncogenic client proteins, giving “polypharmacologic” effects through the targeting of a single, highly networked protein. Hence, the development of small molecule inhibitors of Hsp90 may be effective anti-cancer agents that have reduced likelihood of development of resistance when compared to other less networked single protein targets. This study demonstrates identification and validation of a novel chemotype that perturbs the heat shock protein network. A liquid culture-based phenotypic screen employing Saccharomyces cerevisiae haploid deletions strains with known sensitivities to Hsp90 inhibitors by screening of the NCI diversity II chemical library set. The screen identified 9 hit compounds; 2 previously identified heat shock modulators and 7 novel heat shock modulator hits. To validate these novel compounds as heat shock network selective, we bioinformatically show that the NSC145366 compounds sensitivity profile in NCI tumor cell lines significantly correlates with other Hsp90 inhibitors. Also, biochemical analyses demonstrate NSC145366 has direct interactions with two cytoplasmic isoforms of human Hsp90 both in recombinant protein preparations and in crude tumor cell lysates. In addition, we show that the compound preferentially interacts with the Hsp90 C-terminal dimerization domain as opposed to many of the current N-terminal domain-based inhibitors. Further characterization of the compound interaction with Hsp90 and its effects on the heat shock cellular network are ongoing. This study demonstrates the utility of phenotypic screening to identify heat shock protein network modulators and the possibility inhibiting Hsp90 in a novel and different mode from previous inhibitors.
Citation Format: Kourtney M. Goode, Fiona M. Thomas, Pete Pascuzzi, V. Jo Davisson, Tony R. Hazbun. Mechanistic assessment of heat shock network perturbation by novel chemotypes identified using chemogenomic screening. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B89.
Collapse
|
5
|
Tsai CJ, Aslam K, Drendel HM, Asiago JM, Goode KM, Paul LN, Rochet JC, Hazbun TR. Hsp31 Is a Stress Response Chaperone That Intervenes in the Protein Misfolding Process. J Biol Chem 2015; 290:24816-34. [PMID: 26306045 DOI: 10.1074/jbc.m115.678367] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Indexed: 12/17/2022] Open
Abstract
The Saccharomyces cerevisiae heat shock protein Hsp31 is a stress-inducible homodimeric protein that is involved in diauxic shift reprogramming and has glyoxalase activity. We show that substoichiometric concentrations of Hsp31 can abrogate aggregation of a broad array of substrates in vitro. Hsp31 also modulates the aggregation of α-synuclein (αSyn), a target of the chaperone activity of human DJ-1, an Hsp31 homolog. We demonstrate that Hsp31 is able to suppress the in vitro fibrillization or aggregation of αSyn, citrate synthase and insulin. Chaperone activity was also observed in vivo because constitutive overexpression of Hsp31 reduced the incidence of αSyn cytoplasmic foci, and yeast cells were rescued from αSyn-generated proteotoxicity upon Hsp31 overexpression. Moreover, we showed that Hsp31 protein levels are increased by H2O2, in the diauxic phase of normal growth conditions, and in cells under αSyn-mediated proteotoxic stress. We show that Hsp31 chaperone activity and not the methylglyoxalase activity or the autophagy pathway drives the protective effects. We also demonstrate reduced aggregation of the Sup35 prion domain, PrD-Sup35, as visualized by fluorescent protein fusions. In addition, Hsp31 acts on its substrates prior to the formation of large aggregates because Hsp31 does not mutually localize with prion aggregates, and it prevents the formation of detectable in vitro αSyn fibrils. These studies establish that the protective role of Hsp31 against cellular stress is achieved by chaperone activity that intervenes early in the protein misfolding process and is effective on a wide spectrum of substrate proteins, including αSyn and prion proteins.
Collapse
Affiliation(s)
- Chai-Jui Tsai
- From the Department of Medicinal Chemistry and Molecular Pharmacology and Purdue University Center for Cancer Research and
| | - Kiran Aslam
- From the Department of Medicinal Chemistry and Molecular Pharmacology and Purdue University Center for Cancer Research and
| | - Holli M Drendel
- From the Department of Medicinal Chemistry and Molecular Pharmacology and Purdue University Center for Cancer Research and
| | - Josephat M Asiago
- From the Department of Medicinal Chemistry and Molecular Pharmacology and Purdue University Center for Cancer Research and
| | - Kourtney M Goode
- From the Department of Medicinal Chemistry and Molecular Pharmacology and Purdue University Center for Cancer Research and
| | - Lake N Paul
- the Bindley Bioscience Center, Purdue University, West Lafayette, Indiana 47907
| | - Jean-Christophe Rochet
- From the Department of Medicinal Chemistry and Molecular Pharmacology and Purdue University Center for Cancer Research and
| | - Tony R Hazbun
- From the Department of Medicinal Chemistry and Molecular Pharmacology and Purdue University Center for Cancer Research and
| |
Collapse
|